20421-33-4

Upstream product

• 357-57-3 brucine 
• 3307-39-9 2-(4-chlorophenoxy)propionic acid 
• 156-34-3 l-amphetamine 
• 95262-84-3 2-(4-chlorophenoxy)propanoic acid methyl ester 
• 18672-09-8 (R)-(+)-ethyl 2-(p-chlorophenoxy)propionate 
• 1193-00-6 sodium 4-chlorophenolate 
• 535-11-5 Ethyl 2-bromopropionate 
• 18671-89-1 cyclopropyl 4-(2-chlorophenoxy)butanoate 
• 133707-34-3 2-(4-Chloro-phenoxy)-propionic acid isopropyl ester 
• 139930-23-7 (S)-2-(4-Chloro-phenoxy)-propionic acid butyl ester 
• 186581-53-3 diazomethane 
• 223799-34-6 (S)-2-(4-Chloro-phenoxy)-N-((S)-1-phenyl-ethyl)-propionamide 
• 223799-36-8 (S)-2-(4-Chloro-phenoxy)-N-((R)-1-phenyl-ethyl)-propionamide 
• 18672-08-7 (S)-(-)-ethyl 2-(4-chlorophenoxy)propionate 

Downstream Products

• 92317-69-6 (+)-R-2-<4-Chlorphenoxy>-propionsaeure- 
• 18672-09-8 (R)-(+)-ethyl 2-(p-chlorophenoxy)propionate 
• 99210-92-1 (R)-2-(4-chlorophenoxy)propanoic acid methyl ester 
• 545375-97-1 (-)-(R)-4-methyl-1-[2-(4-chlorophenoxy)-1-oxopropyl]piperidine 
• 155156-11-9 (R)-2-(4-Chloro-phenoxy)-propionic acid (1R,3R,5S)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl ester 
• 21105-14-6 C₉H₈ClNO₅ 
• 94050-90-5 (R)-2-(4-hydroxyphenoxy)propionic acid 
• 87810-51-3 (S)-2-(4-Chloro-phenoxy)-propan-1-ol 
• 545375-98-2 (+)-(S)-4-methyl-1-[2-(4-chlorophenoxy)-1-oxopropyl]piperidine 
• 155156-11-9 (S)-2-(4-Chloro-phenoxy)-propionic acid (1R,3R,5S)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl ester 
• 21237-55-8 C₉H₈ClNO₅ 
• 1030365-55-9 C₁₉H₁₉ClO₅ 
• 1030365-56-0 C₁₉H₁₉ClO₅ 

Relevant academic research and scientific papers

Enantioselectivity of alcohol-treated Candida rugosa lipase in the kinetic resolution of racemic methyl 2-aryloxypropionates in water and aqueous organic media

Racemic methyl 2-aryloxypropionates (±)-1 were subjected to hydrolysis in water and in a series of two-phase aqueous organic media in the presence of Candida rugosa lipase (CRL). The biocatalytic material used was the enzyme of commercial CRL purified by treatment with different alcohols. The purification of CRL and the reaction medium play an important role in the enantioselection of racemates (±)-1. While it is not possible to use the same protocol for all substrates, by combining the different ways of purifying the enzyme with the various reaction media, it is possible to achieve high enantioselectivities of racemic esters. (C) 1999 Elsevier Science Ltd.

Preparation method of (R)-(+)-2-(4-hydroxyphenoxy) propionic acid

The invention provides a preparation method of (R)-(+)-2-(4-hydroxyphenoxy) propionic acid, and belongs to the technical field of pesticide intermediates. Phenol compounds (parachlorophenol, p-bromophenol, p-iodophenol or p-hydroxybenzenesulfonic acid) are adopted as raw materials and react with (S)-(-)-2-chloropropionic acid to synthesize R-(+)-2-(4-chlorophenoxy) propionic acid, and the (R)-(+)-2-(4-hydroxyphenoxy) propionic acid is obtained after hydrogen hydrolysis. The raw material phenol compound used in the invention is low in price and simple in process operation; and the method avoids using hydroquinone as a raw material, and solves the problems of high raw material cost, difficult product purification and low product quality caused by hydroquinone disubstituted impurities generated in the reaction when hydroquinone is used as a raw material for synthesis in the traditional method.

Compounds For The Treatment Of Neuromuscular Disorders

The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the ClC-1 ion channel. The compounds include phenoxy propanoic acid, phenoxy propanoate, and phenoxy butanoate compounds.

Synthesis method of(R)-2-[4-(4-cyano-2-fluorophenoxy)phenoxy] propionic acid

The invention discloses a method for synthesizing cyhalofop butyl intermediate(R)-2-[4-(4-cyano-2-fluorophenoxy)phenoxy] propionic acid.(S)-2-chloropropionic acid methyl ester and p-chlorophenol are used as raw materials, an etherification reaction is performed under an alkaline condition to generate(R)-2-(4-hydroxyphenoxy)propionic acid, and the etherification product and 3-fluoro-4-hydroxybenzonitrile generate the(R)-2-[4-(4-cyano-2-fluorophenoxy)phenoxy] propionic acid under the action of an acid-binding agent. According to the method, the problems of serious excessive hydroquinone servingas a raw material, massive use of an inorganic base and generation of dietherification byproducts in synthesis are avoided. The method is high in atom utilization rate, high in reaction yield and lowin production cost.

Evaluation of the Edman degradation product of vancomycin bonded to core-shell particles as a new HPLC chiral stationary phase

A modified macrocyclic glycopeptide-based chiral stationary phase (CSP), prepared via Edman degradation of vancomycin, was evaluated as a chiral selector for the first time. Its applicability was compared with other macrocyclic glycopeptide-based CSPs: TeicoShell and VancoShell. In addition, another modified macrocyclic glycopeptide-based CSP, NicoShell, was further examined. Initial evaluation was focused on the complementary behavior with these glycopeptides. A screening procedure was used based on previous work for the enantiomeric separation of 50 chiral compounds including amino acids, pesticides, stimulants, and a variety of pharmaceuticals. Fast and efficient chiral separations resulted by using superficially porous (core-shell) particle supports. Overall, the vancomycin Edman degradation product (EDP) resembled TeicoShell with high enantioselectivity for acidic compounds in the polar ionic mode. The simultaneous enantiomeric separation of 5 racemic profens using liquid chromatography-mass spectrometry with EDP was performed in approximately 3?minutes. Other highlights include simultaneous liquid chromatography separations of rac-amphetamine and rac-methamphetamine with VancoShell, rac-pseudoephedrine and rac-ephedrine with NicoShell, and rac-dichlorprop and rac-haloxyfop with TeicoShell.

COMPOUNDS FOR USE IN TREATING NEUROMUSCULAR DISORDERS

The present invention relates to compositions comprising compounds for use in treating, ameliorating and/or preventing neuromuscular disorders. The compounds as defined herein preferably inhibit the ClC-1 ion channel. The invention further relates to methods of treating, preventing and/or ameliorating neuromuscular disorders, by administering said composition to a person in need thereof.

SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME

Disclosed are novel substituted amino triazoles of Formula (I), and pharmaceutically acceptable salts thereof. The compounds of Formula (I) are inhibitors of Acidic mammalian chitinase (AMCase) and are useful, in a non-limiting example, for treating asthma. Also provided are pharmaceutical compositions containing at least one compound of the present invention, or a pharmaceutically acceptable salt, hydrate or solvate thereof, and at least one pharmaceutically acceptable carrier, solvent, adjuvant or diluent, and methods of using such compounds and/or compositions to treat asthma and/or to monitor asthma treatment.

(R,S)-2-chlorophenoxyl pyrazolides as novel substrates for improving lipase-catalyzed hydrolytic resolution

The best reaction condition of Candida antartica lipase B as biocatalyst, 3-(2-pyridyl)pyrazole as leaving azole, and water-saturated methyl t-butyl ether as reaction medium at 45°C were first selected for performing the hydrolytic resolution of (R,S)-2-(4-chlorophenoxyl) azolides (1-4). In comparison with the kinetic resolution of (R,S)-2-phenylpropionyl 3-(2-pyridyl)pyrazolide or (R,S)-α-methoxyphenylacetyl 3-(2-pyridyl)pyrazolide at the same reaction condition, excellent enantioselectivity with more than two order-of-magnitudes higher activity for each enantiomer was obtained. The resolution was then extended to other (R,S)-3-(2-pyridyl)pyrazolides (5-7) containing 2-chloro, 3-chloro, or 2,4-dichloro substituent, giving good (E > 48) to excellent (E > 100) enantioselectivity. The thermodynamic analysis for 1, 2, and 4-7 demonstrates profound effects of the acyl or leaving moiety on varying enthalpic and entropic contributions to the difference of Gibbs free energies. A thorough kinetic analysis further indicates that on the basis of 6, the excellent enantiomeric ratio for 4 and 7 is due to the higher reactivity of (S)-4 and lower reactivity of (R)-7, respectively.

A new method for production of chiral 2-aryloxypropanoic acids using effective kinetic resolution of racemic 2-aryloxycarboxylic acids

We report a novel method for the preparation of 2-aryloxypropanoic acids by kinetic resolution of racemic 2-aryloxypropanoic acids using enantioselective esterification. The usage of pivalic anhydride (Piv2O) as an activating agent, bis(a-naphthyl)methanol ((α-Np)2CHOH) as an achiral alcohol, and (+)-benzotetramisole ((+)-BTM) as a chiral acyl-transfer catalyst enables the effective separation of various racemic 2-aryloxypropanoic acids to afford optically active carboxylic acids and the corresponding esters with high enantioselectivities. Furthermore, theoretical calculations of the transition states required to form the chiral esters successfully proved the enantiomer recognition mechanism of the asymmetric esterification.

Purification and Gene cloning of an enantioselective thioesterification enzyme from Brevibacterium Ketoglutamicum KU1073, a deracemization bacterium of 2-(4-Chlorophenoxy)propanoic acid

We succeeded in the purification and gene cloning of a new enzyme, α-methyl carboxylic acid deracemizing enzyme 1 (MCAD1) from Brevibacterium ketoglutamicum KU1073, which catalyzes the (S)-enantioselective thioesterification reaction of 2-(4-chlorophenoxy)propanoic acid (CPPA). The cloned gene of MCAD1 contained an ORF of 1,623 bp, encoding a polypeptide of 540 amino acids. In combination with cofactors ATP, coenzyme A (CoASH), and Mg 2±, MCAD1 demonstrated perfect enantioselectivity toward CPPA. The optimal pH and temperature for reaction were found to be 7.25 and 30 °C. Under these conditions, the Km and kcat values for (S)-CPPA were 0:92 ± 0:17mM and 0:28 ± 0:026 s-1 respectively. The results for substrate specificity revealed that MCAD1 had highest activity toward fatty acid tails with a medium chain-length (C8). This result indicates that MCAD1 should be classified into a family of medium-chain acyl-CoA synthetase. This novel activity has never been reported for this family.